TYR and neoplasm: Interestingly, Zhou and coworkers developed a tyrosinase (TYR)-MOF employing NPCN-333(Al) as a potent prodrug activator for cancer therapy in HeLa tumor-bearing xenograft mice by tumor-specific prodrug activation 47.